Bold start: Europe’s health future hinges on turning talk into real, on-the-ground change. And this is where the story begins—and why it matters to every citizen. Brussels started the spark; patients must drive the path forward. Now action is essential.
A recent gathering in Brussels, themed From Risk to Action: Preventing liver health crises through NCD literacy and care, highlighted a blunt public health reality: liver disease, MASLD, MASH, and liver cancer are on the rise. They’re often silent, frequently diagnosed late, and yet largely preventable. With energy and expertise, MEP Nicholas Papandreou pressed for a crucial shift: EU health policy must move beyond rhetoric and into concrete steps. The aim is to foster stigma-free awareness that transcends simple lifestyle explanations, prioritize early detection, and enable better, more cohesive care—especially for people carrying multiple health conditions—so they aren’t left directing their own health journeys as if they were the sole decision-maker.
The personal stories shared at the event underscored a vital truth: behind every statistic lies a human life and irreplaceable time. Those testimonies made the case impossible to ignore and set the tone for what must come next.
What began in Brussels has now expanded into a broader effort. Following the event, ELPA was invited to Piraeus, Athens, to scale the liver screening initiative in Greece. The project—led by MEP Nikos Papandreou and implemented in partnership with the Piraeus Medical Association—will bring screening booths directly to communities, making prevention and care more accessible for everyday people.
Greece is poised to become the first EU member state to host, implement, and showcase this innovative approach at scale. It represents a clear demonstration of leadership, collaboration, and European unity at its best: no stigma, no delays, and no more late diagnoses.
The core message is simple but powerful: we must center the patient voice—strong, united, and undeniable—because prevention only works when it reaches real people in real places,—and when patient organizations like ELPA, clinicians, and policymakers work side by side. Brussels sparked the idea; Piraeus will demonstrate its viability; and Europe must scale it across the continent.
This is more than advocacy—it’s a blueprint for turning awareness into action, and a call to everyone: how will you participate in this movement to protect liver health in your community?
